Retatrutide + Tirzepatide Combo
Triple-receptor and dual-receptor incretins combined for research into maximal GLP-1/GIP/glucagon axis engagement. For comparative pharmacology and
Buy more, save more
Total Price
$280
For research & laboratory use only. Not for human consumption.
Half-Life
Retatrutide: ~6 days; Tirzepatide: ~5 days
Administration Route
Subcutaneous injection
Effect Profile
Combined Efficacy
Synergistic Action
Protocol Coverage
Value
Mechanism of Action
Product FAQs
Stacks Well With
Retatrutide
Triple GLP-1, GIP, and glucagon receptor agonist. Phase 2 data reported up to 24.2% body weight reduction at 12mg weekly dose over 48 weeks.
Tirzepatide
Dual GIP and GLP-1 receptor agonist. Among the most potent metabolic peptides studied to date, with clinical trials reporting up to 21% body weight reduction.
Related Products
Retatrutide
Triple GLP-1, GIP, and glucagon receptor agonist. Phase 2 data reported up to 24.2% body weight reduction at 12mg weekly dose over 48 weeks.
Tirzepatide
Dual GIP and GLP-1 receptor agonist. Among the most potent metabolic peptides studied to date, with clinical trials reporting up to 21% body weight reduction.
Semaglutide
Long-acting GLP-1 receptor agonist. STEP-1 trial reported 14.9% average body weight reduction at 2.4mg weekly dose over 68 weeks.